Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Redefining How A Chronic Auto-Immune Disease Is Diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Electrodiagnostic Neuromuscular Lab at JHN, led the study which looked at the number of demyelinating features that are needed to differentiate between CIDP, Amyotrophic lateral sclerosis (ALS, or Lou Gehrig"s disease) and diabetic neuropathy. His research suggests a minimum number of three demyelinating features can be used to positively identify CIDP in a patient. CIDP is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It affects about 50,000 people in the United States. The study, available in the current edition of the Journal of Clinical Neuromuscular Disease, may help doctors more effectively diagnose and treat CIDP.
generic viagra online
Which Country Ranks Highest In Biotech Innovation
In a first of its kind study, Scientific American cut through the marketing messages to take a hard look at what countries across the globe are doing to bolster biotech programs within their borders. Many rankings compare Europe, Asia, and the US -- the Scientific American Worldview: A Global Biotechnology Perspective digs deeper, examining all the elements that impact overall biotech innovation. You might be surprised by some of the results.
News of the day
King Provides Additional Information On The REMOXY® NDA Resubmission Plan
King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY® New Drug Application (NDA). The Company is not required by the Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate to severe chronic pain. However, as part of the resubmission plan, and in order to strengthen the NDA, King plans to conduct a likeability study and a pharmacokinetic trial in volunteers. The Company continues to anticipate the resubmission could occur mid-year 2010.
Diagnostics

Promedior Initiates Phase 1 Clinical Trial Of PRM-151, A Novel Compound For The Treatment Of Fibrotic Diseases And Tissue Remodeling

Promedior, Inc. announced the initiation of a Phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The Phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects. The study is being conducted at the Centre for Human Drug Research in The Netherlands. PRM-151(rhSAP) is a recombinant form of human Serum Amyloid P, a highly conserved natural human protein that mediates its anti-fibrotic activity by targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated an outstanding preclinical safety profile and robust preclinical efficacy by reducing fibrosis in multiple tissues, organs, and disease models. "The initiation of the Phase 1 clinical trial of PRM-151 represents an important milestone in the development of Promedior"s novel platform of products for the treatment of fibrotic diseases," said Dominick Colangelo, Chief Executive Officer of Promedior. "We believe that PRM-151 has tremendous potential to play an important role in improving patient outcomes across multiple disease indications and will position Promedior in a leadership position in the development of innovative anti-fibrotic therapeutics." "Through its fundamental role in regulating monocyte responses to injured tissue, we believe PRM-151 affects a common biology present in all forms of pathologic fibrosis," commented Dr. Mark Lupher, Jr., the company"s Senior Vice President of Discovery Research. "In collaboration with leading investigators at Harvard University, Yale University, University of Michigan, University of California San Diego and Rice University, we have consistently demonstrated significant anti-fibrotic activity across model systems, including in established disease settings, and are very excited to advance this novel compound into clinical research." Promedior, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009